These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 39236245)

  • 21. SARS-CoV-2 M
    Lis K; Plewka J; Menezes F; Bielecka E; Chykunova Y; Pustelny K; Niebling S; Garcia AS; Garcia-Alai M; Popowicz GM; Czarna A; Kantyka T; Pyrc K
    Int J Biol Macromol; 2024 May; 267(Pt 1):131392. PubMed ID: 38582483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Resistance-associated mutations to the anti-SARS-CoV-2 agent nirmatrelvir: Selection not induction.
    Colson P; Delerce J; Pontarotti P; Devaux C; La Scola B; Fantini J; Raoult D
    J Med Virol; 2024 Feb; 96(2):e29462. PubMed ID: 38363015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19.
    Hoffman RL; Kania RS; Brothers MA; Davies JF; Ferre RA; Gajiwala KS; He M; Hogan RJ; Kozminski K; Li LY; Lockner JW; Lou J; Marra MT; Mitchell LJ; Murray BW; Nieman JA; Noell S; Planken SP; Rowe T; Ryan K; Smith GJ; Solowiej JE; Steppan CM; Taggart B
    J Med Chem; 2020 Nov; 63(21):12725-12747. PubMed ID: 33054210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The small molecule inhibitor of SARS-CoV-2 3CLpro EDP-235 prevents viral replication and transmission in vivo.
    Rhodin MHJ; Reyes AC; Balakrishnan A; Bisht N; Kelly NM; Gibbons JS; Lloyd J; Vaine M; Cressey T; Crepeau M; Shen R; Manalo N; Castillo J; Levene RE; Leonard D; Zang T; Jiang L; Daniels K; Cox RM; Lieber CM; Wolf JD; Plemper RK; Leist SR; Scobey T; Baric RS; Wang G; Goodwin B; Or YS
    Nat Commun; 2024 Aug; 15(1):6503. PubMed ID: 39090095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir.
    Iketani S; Mohri H; Culbertson B; Hong SJ; Duan Y; Luck MI; Annavajhala MK; Guo Y; Sheng Z; Uhlemann AC; Goff SP; Sabo Y; Yang H; Chavez A; Ho DD
    Nature; 2023 Jan; 613(7944):558-564. PubMed ID: 36351451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening of M
    Altomare A; Baron G; Cambiaghi G; Ferrario G; Zoanni B; Della Vedova L; Fumagalli GM; D'Alessandro S; Parapini S; Vittorio S; Vistoli G; Riso P; Carini M; Delbue S; Aldini G
    Molecules; 2024 Jun; 29(11):. PubMed ID: 38893578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir.
    Ullrich S; Ekanayake KB; Otting G; Nitsche C
    Bioorg Med Chem Lett; 2022 Apr; 62():128629. PubMed ID: 35182772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors.
    Huff S; Kummetha IR; Tiwari SK; Huante MB; Clark AE; Wang S; Bray W; Smith D; Carlin AF; Endsley M; Rana TM
    J Med Chem; 2022 Feb; 65(4):2866-2879. PubMed ID: 34570513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structural basis for the inhibition of the HCoV-NL63 main protease M
    Xu J; Zhu Q; Li W; Yin X; Li J
    Biochem Biophys Res Commun; 2024 Sep; 724():150231. PubMed ID: 38852502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Insights into the Main Protease of SARS-CoV-2: Thermodynamic Analysis, Structural Characterization, and the Impact of Inhibitors.
    Butalewicz JP; Sipe SN; Juetten KJ; James VK; Kim K; Zhang YJ; Meek TD; Brodbelt JS
    Anal Chem; 2024 Oct; 96(40):15898-15906. PubMed ID: 39319663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repurposing an Antiviral Drug against SARS-CoV-2 Main Protease.
    Sarkar A; Mandal K
    Angew Chem Int Ed Engl; 2021 Oct; 60(44):23492-23494. PubMed ID: 34545983
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
    Brewitz L; Kamps JJAG; Lukacik P; Strain-Damerell C; Zhao Y; Tumber A; Malla TR; Orville AM; Walsh MA; Schofield CJ
    ChemMedChem; 2022 May; 17(9):e202200016. PubMed ID: 35085423
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease.
    Noske GD; de Souza Silva E; de Godoy MO; Dolci I; Fernandes RS; Guido RVC; Sjö P; Oliva G; Godoy AS
    J Biol Chem; 2023 Mar; 299(3):103004. PubMed ID: 36775130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
    Günther S; Reinke PYA; Fernández-García Y; Lieske J; Lane TJ; Ginn HM; Koua FHM; Ehrt C; Ewert W; Oberthuer D; Yefanov O; Meier S; Lorenzen K; Krichel B; Kopicki JD; Gelisio L; Brehm W; Dunkel I; Seychell B; Gieseler H; Norton-Baker B; Escudero-Pérez B; Domaracky M; Saouane S; Tolstikova A; White TA; Hänle A; Groessler M; Fleckenstein H; Trost F; Galchenkova M; Gevorkov Y; Li C; Awel S; Peck A; Barthelmess M; Schlünzen F; Lourdu Xavier P; Werner N; Andaleeb H; Ullah N; Falke S; Srinivasan V; França BA; Schwinzer M; Brognaro H; Rogers C; Melo D; Zaitseva-Kinneberg JI; Knoska J; Peña-Murillo GE; Mashhour AR; Hennicke V; Fischer P; Hakanpää J; Meyer J; Gribbon P; Ellinger B; Kuzikov M; Wolf M; Beccari AR; Bourenkov G; von Stetten D; Pompidor G; Bento I; Panneerselvam S; Karpics I; Schneider TR; Garcia-Alai MM; Niebling S; Günther C; Schmidt C; Schubert R; Han H; Boger J; Monteiro DCF; Zhang L; Sun X; Pletzer-Zelgert J; Wollenhaupt J; Feiler CG; Weiss MS; Schulz EC; Mehrabi P; Karničar K; Usenik A; Loboda J; Tidow H; Chari A; Hilgenfeld R; Uetrecht C; Cox R; Zaliani A; Beck T; Rarey M; Günther S; Turk D; Hinrichs W; Chapman HN; Pearson AR; Betzel C; Meents A
    Science; 2021 May; 372(6542):642-646. PubMed ID: 33811162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of bio-active Amaryllidaceae alkaloidal small molecules as putative SARS-CoV-2 main protease and host TMPRSS2 inhibitors: interpretation by
    Bhowmick S; Mistri TK; Khan MR; Patil PC; Busquets R; Ashif Ikbal AM; Choudhury A; Roy DK; Palit P; Saha A
    J Biomol Struct Dyn; 2024 Sep; 42(14):7107-7127. PubMed ID: 37482789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SARS-CoV-2 M
    Rut W; Groborz K; Zhang L; Sun X; Zmudzinski M; Pawlik B; Wang X; Jochmans D; Neyts J; Młynarski W; Hilgenfeld R; Drag M
    Nat Chem Biol; 2021 Feb; 17(2):222-228. PubMed ID: 33093684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Natural Polyphenols Inhibit the Dimerization of the SARS-CoV-2 Main Protease: The Case of Fortunellin and Its Structural Analogs.
    Panagiotopoulos AA; Karakasiliotis I; Kotzampasi DM; Dimitriou M; Sourvinos G; Kampa M; Pirintsos S; Castanas E; Daskalakis V
    Molecules; 2021 Oct; 26(19):. PubMed ID: 34641612
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

  • 39. SARS-CoV-2 M
    Citarella A; Scala A; Piperno A; Micale N
    Biomolecules; 2021 Apr; 11(4):. PubMed ID: 33921886
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nirmatrelvir and molnupiravir maintain potent in vitro and in vivo antiviral activity against circulating SARS-CoV-2 omicron subvariants.
    Rosales R; McGovern BL; Rodriguez ML; Leiva-Rebollo R; Diaz-Tapia R; Benjamin J; Rai DK; Cardin RD; Anderson AS; ; Sordillo EM; van Bakel H; Simon V; García-Sastre A; White KM
    Antiviral Res; 2024 Oct; 230():105970. PubMed ID: 39067667
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.